Concepedia

Paul Tardi

PT

Statistics

Publications

31

Citations

2.3K

H-Index

24

Active since

1992

Affiliations

Celator Pharmaceuticals (Canada)(Current)

BC Cancer Agency

University of British Columbia

University of Manitoba

Inimex Pharmaceuticals (Canada)

Paul Tardi is an author at Celator Pharmaceuticals (Canada) specializing in pharmacology, drug delivery, and liposomes.

Publications per year

1992–2020

31

Publications

31

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy

Paul Tardi, Sharon A. Johnstone, Natashia Harasym et al. · Leukemia Research · 2008 · 354 citations

, , +8

Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

Lawrence D. Mayer, Troy O. Harasym, Paul Tardi et al. · Molecular Cancer Therapeutics · 2006 · 326 citations · Full text

, , +15

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts

Wah-Seng Lim, Paul Tardi, Nancy Dos Santos et al. · Leukemia Research · 2010 · 159 citations

, , +17

Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.

Paul Tardi, EDWARD CHOICE, Dana Masin et al. · PubMed · 2000 · 159 citations · Full text

, , +16

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo

Paul Tardi, Ryan Gallagher, Sharon A. Johnstone et al. · Biochimica et Biophysica Acta (BBA) - Biomembranes · 2006 · 133 citations

, , +14

1–5 of 31